Scientific tests provide data within a probabilistic context. The performance characteristics of the chemosensitivity assay technique, established in more than 500 published clinical correlations, provides sensitivity of 94 percent and specificity of 71 percent.1
Yet, treating physicians must depend on the more clinically relevant statistical measures, which are influenced by the true responsiveness of the specific disease in question (e.g. childhood leukemia is by nature more chemo-responsive than adult colon cancer). This explains the all-too-familiar but inaccurate saying, "Chemosensitivity tests are good for selecting what won't work, but are not good for selecting what will!"
Actually, the Rational Therapeutics EVA-PCD platform is very good at finding effective drugs, but only if effective drugs are there to be found. Therefore, it is critical that the treating oncologist examine laboratory results within the clinical context of each diagnosis. This constitutes an important advantage of Rational Therapeutics' approach over prior investigations in this field.